JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation

Journal of Dermatological Science

Volumn 84, Issue 3, 2016, Pages 258-265

  Amano, Wataru ^a,b   Nakajima, Saeko ^a   Yamamoto, Yasuo ^a,b   Tanimoto, Atsuo ^b   Matsushita, Mutsuyoshi ^b   Miyachi, Yoshiki ^a   Kabashima, Kenji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

Contact hypersensitivity; Cytokines; Effector memory T cell; JAK STAT; Skin inflammation

Indexed keywords

CROTON OIL; CYTOKINE; JANUS KINASE INHIBITOR; JTE 052; UNCLASSIFIED DRUG; GAMMA INTERFERON; HAPTEN; INTERLEUKIN 13; INTERLEUKIN 17; JTE-052; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTACT ALLERGY; DENDRITIC CELL; DERMATITIS; EAR; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOMODULATION; IRRITANT DERMATITIS; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE TRANSFER; MOUSE; MURINE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; DERMATITIS, ALLERGIC CONTACT; DRUG EFFECTS; FEMALE; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PRECLINICAL STUDY; SKIN; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGEN PRESENTATION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CROTON OIL; DENDRITIC CELLS; DERMATITIS, ALLERGIC CONTACT; DRUG EVALUATION, PRECLINICAL; FEMALE; HAPTENS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PROTEIN KINASE INHIBITORS; PYRROLES; SKIN; T-LYMPHOCYTES;

EID: 84994479671     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2016.09.007     Document Type: Article

References (34)

1. [1] Honda, T., Egawa, G., Grabbe, S., Kabashima, K., Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J. Invest. Dermatol. 133 (2013), 303–315.
2. [2] Kaplan, D.H., Igyarto, B.Z., Gaspari, A.A., Early immune events in the induction of allergic contact dermatitis. Nat. Rev. Immunol. 12 (2012), 114–124.
3. [3] Smith, H.R., Basketter, D.A., McFadden, J.P., Irritant dermatitis, irritancy and its role in allergic contact dermatitis. Clin. Exp. Dermatol. 27 (2002), 138–146.
4. [4] Martin, S.F., Allergic contact dermatitis: xenoinflammation of the skin. Curr. Opin. Immunol. 24 (2012), 720–729.
5. [5] Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000), 767–811.
6. [6] Mori, T., Kabashima, K., Yoshiki, R., Sugita, K., Shiraishi, N., Onoue, A., et al. Cutaneous hypersensitivities to hapten are controlled by IFN-gamma-upregulated keratinocyte Th1 chemokines and IFN-gamma-downregulated langerhans cell Th2 chemokines. J. Invest. Dermatol. 128 (2008), 1719–1727.
7. [7] Shuai, K., Liu, B., Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3 (2003), 900–911.
8. [8] O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
9. [9] Laurence, A., Pesu, M., Silvennoinen, O., O'Shea, J., JAK kinases in health and disease: an update. Open Rheumatol. J. 6 (2012), 232–244.
10. [10] Ghoreschi, K., Jesson, M.I., Li, X., Lee, J.L., Ghosh, S., Alsup, J.W., et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J. Immunol. 186 (2011), 4234–4243.
11. [11] Migita, K., Miyashita, T., Izumi, Y., Koga, T., Komori, A., Maeda, Y., et al. Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production. BMC Immunol., 12, 2011, 51.
12. [12] Heine, A., Held, S.A., Daecke, S.N., Wallner, S., Yajnanarayana, S.P., Kurts, C., et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122 (2013), 1192–1202.
13. [13] Fridman, J.S., Scherle, P.A., Collins, R., Burn, T., Neilan, C.L., Hertel, D., et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J. Invest. Dermatol. 131 (2011), 1838–1844.
14. [14] Tanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm. Res. 64 (2015), 41–51.
15. [15] Amano, W., Nakajima, S., Kunugi, H., Numata, Y., Kitoh, A., Egawa, G., et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J. Allergy Clin. Immunol. 136 (2015), 667–677.
16. [16] Nakajima, S., Honda, T., Sakata, D., Egawa, G., Tanizaki, H., Otsuka, A., et al. Prostaglandin I2-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity. J. Immunol. 184 (2010), 5595–5603.
17. [17] Nakashima, C., Otsuka, A., Kitoh, A., Honda, T., Egawa, G., Nakajima, S., et al. Basophils regulate the recruitment of eosinophils in a murine model of irritant contact dermatitis. J. Allergy Clin. Immunol. 134 (2014), 100–107.
18. [18] Liu, W.H., Liu, J.J., Wu, J., Zhang, L.L., Liu, F., Yin, L., et al. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One, 8, 2013, e55487.
19. [19] Fujii, Y., Sengoku, T., Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis. Pharmacol 91 (2013), 207–213.
20. [20] Zhong, J., Yang, P., Muta, K., Dong, R., Marrero, M., Gong, F., et al. Loss of Jak2 selectively suppresses DC-mediated innate immune response and protects mice from lethal dose of LPS-induced septic shock. PLoS One, 5, 2010, e9593.
21. [21] Egawa, G., Kabashima, K., Skin as a peripheral lymphoid organ: revisiting the concept of skin-associated lymphoid tissues. J. Invest. Dermatol. 131 (2011), 2178–2185.
22. [22] Ono, S., Kabashima, K., Proposal of inducible skin-associated lymphoid tissue (iSALT). Exp. Dermatol. 24 (2015), 630–631.
23. [23] Natsuaki, Y., Egawa, G., Nakamizo, S., Ono, S., Hanakawa, S., Okada, T., et al. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin. Nat. Immunol. 15 (2014), 1064–1069.
24. [24] Dufour, J.H., Dziejman, M., Liu, M.T., Leung, J.H., Lane, T.E., Luster, A.D., IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168 (2002), 3195–3204.
25. [25] Akiba, H., Kehren, J., Ducluzeau, M.T., Krasteva, M., Horand, F., Kaiserlian, D., et al. Skin inflammation during contact hypersensitivity is mediated by early recruitment of CD8+ T cytotoxic 1 cells inducing keratinocyte apoptosis. J. Immunol. 168 (2002), 3079–3087.
26. [26] Dustin, M.L., Singer, K.H., Tuck, D.T., Springer, T.A., Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J. Exp. Med. 167 (1988), 1323–1340.
27. [27] Yusuf-Makagiansar, H., Anderson, M.E., Yakovleva, T.V., Murray, J.S., Siahaan, T.J., Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res. Rev. 22 (2002), 146–167.
28. [28] Sladojevic, N., Stamatovic, S.M., Keep, R.F., Grailer, J.J., Sarma, J.V., Ward, P.A., et al. Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury. Neurobiol. Dis. 67 (2014), 57–70.
29. [29] Chang, B.Y., Zhao, F., He, X., Ren, H., Braselmann, S., Taylor, V., et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J. Immunol. 183 (2009), 2183–2192.
30. [30] Papp, K.A., Menter, M.A., Abe, M., Elewski, B., Feldman, S.R., Gottlieb, A.B., et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br. J. Dermatol. 173 (2015), 949–961.
31. [31] Xing, L., Dai, Z., Jabbari, A., Cerise, J.E., Higgins, C.A., Gong, W., et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat. Med. 20 (2014), 1043–1049.
32. [32] Kabashima, K., New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J. Dermatol. Sci. 70:1 (2013), 3–11.
33. [33] Dainichi, T., Hanakawa, S., Kabashima, K., Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. J. Dermatol. Sci. 76:2 (2014), 81–89.
34. [34] Egawa, G., Kabashima, K., Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J. Allergy Clin. Immunol. 138 (2016), 350–358.